Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.4 USD | -0.73% | -4.00% | +57.82% |
13/05 | Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab | MT |
13/05 | Merus Carcinoma Treatment Awarded US FDA's Breakthrough Therapy Designation | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+57.82% | 254.7Cr | |
+9.99% | 12TCr | |
+12.01% | 11TCr | |
-3.07% | 2.47TCr | |
-0.96% | 2.2TCr | |
-4.92% | 1.93TCr | |
-6.90% | 1.76TCr | |
-39.36% | 1.73TCr | |
+5.82% | 1.4TCr | |
+33.05% | 1.21TCr |
- Stock Market
- Equities
- MRUS Stock
- News Merus N.V.
- Insider Trends: 90-Day Buying Trend Extended with Insider Purchase of Merus NV Stock